Church & Dwight CO Inc CHD
We take great care to ensure that the data presented and summarized in this overview for CHURCH & DWIGHT CO INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CHD
View all-
Vanguard Group Inc Valley Forge, PA30.5MShares$3.39 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY20.9MShares$2.33 Billion0.05% of portfolio
-
State Street Corp Boston, MA13.1MShares$1.46 Billion0.06% of portfolio
-
Capital International Investors Los Angeles, CA9.34MShares$1.04 Billion0.19% of portfolio
-
Massachusetts Financial Services CO Boston, MA8.02MShares$892 Million0.26% of portfolio
-
Terry Smith Fundsmith LLP | London, X06.88MShares$766 Million2.92% of portfolio
-
Jpmorgan Chase & CO New York, NY6.15MShares$684 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA5.77MShares$642 Million0.05% of portfolio
-
Stifel Financial Corp St. Louis, MO4.3MShares$478 Million0.48% of portfolio
-
Morgan Stanley New York, NY3.57MShares$397 Million0.03% of portfolio
Latest Institutional Activity in CHD
Top Purchases
Top Sells
About CHD
Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.
Insider Transactions at CHD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 12
2024
|
Bradley C Irwin Director |
SELL
Open market or private sale
|
Direct |
13,200
-15.08%
|
$1,412,400
$107.44 P/Share
|
Nov 12
2024
|
Bradley C Irwin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,200
+13.1%
|
$660,000
$50.28 P/Share
|
Nov 07
2024
|
Matthew Farrell President and CEO |
SELL
Open market or private sale
|
Direct |
34,177
-23.27%
|
$3,554,408
$104.3 P/Share
|
Nov 07
2024
|
Matthew Farrell President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,177
+18.87%
|
$1,708,850
$50.28 P/Share
|
Nov 06
2024
|
Matthew Farrell President and CEO |
SELL
Open market or private sale
|
Direct |
300,000
-57.03%
|
$30,900,000
$103.84 P/Share
|
Nov 06
2024
|
Matthew Farrell President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+36.31%
|
$15,600,000
$52.01 P/Share
|
Nov 05
2024
|
Matthew Farrell President and CEO |
SELL
Open market or private sale
|
Direct |
100,000
-47.01%
|
$10,400,000
$104.0 P/Share
|
Nov 05
2024
|
Matthew Farrell President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+31.98%
|
$5,300,000
$53.75 P/Share
|
Nov 04
2024
|
Matthew Farrell President and CEO |
SELL
Open market or private sale
|
Direct |
165,823
-32.1%
|
$17,079,769
$103.03 P/Share
|
Nov 04
2024
|
Matthew Farrell President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
165,823
+21.15%
|
$7,793,681
$47.75 P/Share
|
Nov 04
2024
|
Arthur B Winkleblack Director |
SELL
Open market or private sale
|
Direct |
11,590
-44.84%
|
$1,193,770
$103.84 P/Share
|
Nov 04
2024
|
Arthur B Winkleblack Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,590
+30.96%
|
$614,270
$53.75 P/Share
|
Oct 01
2024
|
Kevin Gokey Executive VP, CIO |
BUY
Grant, award, or other acquisition
|
Direct |
450
+30.97%
|
-
|
Oct 01
2024
|
Surabhi Pokhriyal EVP, Chief Digital Growth Off |
BUY
Grant, award, or other acquisition
|
Direct |
330
+21.47%
|
-
|
Sep 23
2024
|
Ravichandra Krishnamurty Saligram Director |
SELL
Bona fide gift
|
Indirect |
46
-0.17%
|
-
|
Aug 05
2024
|
Barry A. Bruno EVP, Chf Mktng Offcr Pres CD |
SELL
Open market or private sale
|
Direct |
59,328
-69.47%
|
$5,873,472
$99.37 P/Share
|
Aug 05
2024
|
Barry A. Bruno EVP, Chf Mktng Offcr Pres CD |
BUY
Exercise of conversion of derivative security
|
Direct |
59,328
+40.84%
|
$4,034,304
$68.37 P/Share
|
Jul 08
2024
|
Michael R Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
760
+50.0%
|
-
|
Jun 30
2024
|
Laurie Yoler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,158
+10.87%
|
$119,274
$103.68 P/Share
|
Jun 30
2024
|
Susan G Saideman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,158
+16.25%
|
$119,274
$103.68 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 29.1K shares |
---|---|
Exercise of conversion of derivative security | 1.66M shares |
Open market or private sale | 1.68M shares |
---|---|
Payment of exercise price or tax liability | 2.35K shares |
Bona fide gift | 7.24K shares |